Clearside Biomedical (NASDAQ:CLSD – Get Free Report) will be announcing its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.
Clearside Biomedical (NASDAQ:CLSD – Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04. The business had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.25 million. During the same period in the previous year, the business posted ($0.15) earnings per share. On average, analysts expect Clearside Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Clearside Biomedical Price Performance
CLSD opened at $1.14 on Friday. The stock has a market capitalization of $85.19 million, a price-to-earnings ratio of -2.28 and a beta of 2.33. Clearside Biomedical has a 12 month low of $0.76 and a 12 month high of $2.12. The business has a 50-day moving average of $1.18 and a two-hundred day moving average of $1.19.
Wall Street Analyst Weigh In
Read Our Latest Stock Report on Clearside Biomedical
Insider Buying and Selling
In related news, insider Ngai Hang Victor Chong bought 36,500 shares of the stock in a transaction dated Friday, November 1st. The stock was acquired at an average price of $1.00 per share, for a total transaction of $36,500.00. Following the completion of the purchase, the insider now owns 100,000 shares in the company, valued at $100,000. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.20% of the stock is owned by corporate insiders.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Recommended Stories
- Five stocks we like better than Clearside Biomedical
- Investing In Automotive Stocks
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Why Invest in 5G? How to Invest in 5G Stocks
- MarketBeat Week in Review – 11/4 – 11/8
- Stock Market Upgrades: What Are They?
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.